MHC
RLMD icon

Meyer Handelman Company’s Relmada Therapeutics RLMD Stock Holding History

Meyer Handelman Company’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-32,545
Closed -$151K – 209
2024
Q1 		$151K Hold
32,545
– – 0.01% 200
2023
Q4 		$135K Hold
32,545
– – 0.01% 187
2023
Q3 		$97.6K Hold
32,545
– – ﹤0.01% 189
2023
Q2 		$80.1K Hold
32,545
– – ﹤0.01% 184
2023
Q1 		$73.6K Hold
32,545
– – ﹤0.01% 181
2022
Q4 		$114K Hold
32,545
– – ﹤0.01% 186
2022
Q3 		$1.21M Hold
32,545
– – 0.06% 136
2022
Q2 		$618K Hold
32,545
– – 0.03% 157
2022
Q1 		$878K Hold
32,545
– – 0.03% 149
2021
Q4 		$733K Buy
32,545
+4,167
+15% +$92.7K 0.03% 152
2021
Q3 		$744K Hold
28,378
– – 0.03% 156
2021
Q2 		$908K Hold
28,378
– – 0.04% 151
2021
Q1 		$999K Sell
28,378
-16,666
-37% -$583K 0.04% 149
2020
Q4 		$1.45M Buy
45,044
+16,666
+59% +$573K 0.07% 129
2020
Q3 		$1.07M Hold
28,378
– – 0.05% 132
2020
Q2 		$1.27M Hold
28,378
– – 0.07% 129
2020
Q1 		$968K Sell
28,378
-2,000
-7% -$80.6K 0.06% 129
2019
Q4 		$1.19M Buy
+30,378
New +$923K 0.06% 134

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Meyer Handelman Company's RLMD Position: Q2 2024 in Review

Meyer Handelman Company sold out of Relmada Therapeutics (RLMD) in Q2 2024, closing a stake of 32,545 shares — an estimated $151K sold.

Meyer Handelman Company first reported a position in RLMD in Q4 2019 and held it in 18 quarters. The position peaked at $1.45M in Q4 2020. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

  • Meyer Handelman Company reported no remaining Relmada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Meyer Handelman Company sold 32,545 Relmada Therapeutics shares in Q2 2024, an estimated $151K.
  • Meyer Handelman Company first reported a position in Relmada Therapeutics in Q4 2019 and held it in 18 quarters.
  • Meyer Handelman Company's Relmada Therapeutics position peaked at $1.45M in Q4 2020.
  • 79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on Meyer Handelman Company's 13F filing for Q2 2024, filed 16 Jul 2024.